Postoperative adjuvant therapy for resectable early non-small cell lung cancer A protocol for a systematic review and meta-analysis

被引:5
|
作者
Chai, Tianci [1 ,2 ]
Zhang, Peipei [1 ,2 ]
Lin, Yuhan [3 ]
Zhang, Zhenyang [1 ]
Lin, Wenwei [1 ]
Kang, Mingqiang [1 ]
Lin, Jiangbo [1 ]
机构
[1] Fujian Med Univ, Union Hosp, Dept Thorac Surg, 29 New Power Rd, Fuzhou 350004, Fujian, Peoples R China
[2] Fujian Med Univ, Grad Sch, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Sch Stomatol, Fuzhou, Fujian, Peoples R China
关键词
chemotherapy; immunotherapy; molecular targeted therapy; non-small cell lung cancer; radiotherapy; STAGE-II;
D O I
10.1097/MD.0000000000016468
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Lung cancer is one of the most common malignant tumors, and non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer diagnosed. For patients with resectable early stage non-small cell lung cancer, routine postoperative adjuvant therapy can significantly prolong overall patient survival and reduce the risk of cancer recurrence. With the emergence and maturity of molecular targeted therapy and immunotherapy, the postoperative chemotherapy strategy of lung cancer patients has changed a lot. To evaluate the efficacy of postoperative adjuvant therapy (platinum-based chemotherapy, platinum-based chemotherapy plus molecular targeted therapy, platinum-based chemotherapy plus anti-angiogenic agents, or platinum-based chemotherapy plus immunotherapy) with or without radiotherapy for patients with NSCLC, we will conduct a systematic review and meta-analysis of the published or unpublished relevant randomized controlled trials. Methods: We will search PubMed (Medline), Embase, Google Scholar, Cancerlit, and the Cochrane Central Register of Controlled Trials for related studies published without language restrictions before June 20, 2019. Two review authors will search and assess relevant studies independently. Randomized controlled trials (RCTs) and quasi-RCTs studies will be included. We will perform subgroup analysis in different methods of postoperative adjuvant therapy for patients with resectable early NSCLC. Because this study will be based on published or unpublished records and studies, there is no need for ethics approval. Results: The results of this study will be published in a peer-reviewed journal. Conclusion: This study will comprehensively compare the efficacy of platinum-based chemotherapy with that of molecular targeted therapy and immunotherapy for patients after surgery with resectable early NSCLC. Since large-sample randomized trials meeting the inclusion criteria of this study may be insufficient, we will consider incorporating some high-quality small-sample-related trials, which may lead to high heterogeneity and affect the reliability of the results.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature
    Berghmans, T
    Paesmans, M
    Meert, AP
    Mascaux, C
    Lothaire, P
    Lafitte, JJ
    Sculier, JP
    LUNG CANCER, 2005, 49 (01) : 13 - 23
  • [32] Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol
    Li, Feng
    Liu, Guangyu
    Roudi, Raheleh
    Huang, Qi
    Swierzy, Marc
    Ismail, Mahmoud
    Zhao, Song
    Rueckert, Jens-Carsten
    BMJ OPEN, 2018, 8 (09): : e022161
  • [33] Protocol for a systematic review and meta-analysis of recurrence and metastasis of different surgical techniques for non-small cell lung cancer
    Huang, Xiongfeng
    Zhu, Donghong
    Cao, Yaoxing
    Li, Weijuan
    Lai, Jinxing
    Ren, Yuxi
    BMJ OPEN, 2024, 14 (08):
  • [34] Efficacy of weekly amrubicin for refractory or relapsed non-small cell lung cancer A protocol of systematic review and meta-analysis
    Dang, Dong
    Jiang, Chao
    Xie, Ming-rui
    MEDICINE, 2020, 99 (25) : E20454
  • [35] Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
    Richard A Malthaner
    Rebecca KS Wong
    R Bryan Rumble
    Lisa Zuraw
    BMC Medicine, 2
  • [36] Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
    Malthaner, Richard A.
    Wong, Rebecca K. S.
    Rumble, R. Bryan
    Zuraw, Lisa
    BMC MEDICINE, 2004, 2 (1)
  • [37] Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis
    Waser, N. A.
    Adam, A.
    Schweikert, B.
    Vo, L.
    McKenna, M.
    Breckenridge, M.
    Penrod, J. R.
    Goring, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S806 - S806
  • [38] Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
    Jiang, Juan
    Wang, Yuling
    Gao, Yang
    Sugimura, Haruhiko
    Minervini, Fabrizio
    Uchino, Junji
    Halmos, Balazs
    Yendamuri, Sai
    Velotta, Jeffrey B.
    Li, Min
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (02) : 277 - +
  • [39] Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis
    Kuo, Wei-Ke
    Weng, Ching-Fu
    Lien, Yin-Ju
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [40] ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
    Elliott, Jesse
    Bai, Zemin
    Hsieh, Shu-Ching
    Kelly, Shannon E.
    Chen, Li
    Skidmore, Becky
    Yousef, Said
    Zheng, Carine
    Stewart, David J.
    Wells, George A.
    PLOS ONE, 2020, 15 (02):